Seven Fleet Capital Management LP Buys 457,804 Shares of Pharvaris N.V. $PHVS

Seven Fleet Capital Management LP boosted its stake in shares of Pharvaris N.V. (NASDAQ:PHVS) by 144.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 774,501 shares of the company’s stock after acquiring an additional 457,804 shares during the quarter. Pharvaris accounts for 4.4% of Seven Fleet Capital Management LP’s portfolio, making the stock its 4th largest position. Seven Fleet Capital Management LP owned about 1.18% of Pharvaris worth $26,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in PHVS. Quantbot Technologies LP bought a new position in Pharvaris in the 2nd quarter valued at $41,000. JPMorgan Chase & Co. grew its holdings in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. Barclays PLC bought a new stake in shares of Pharvaris during the fourth quarter worth $77,000. CoreCap Advisors LLC acquired a new stake in shares of Pharvaris in the second quarter valued at $93,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Pharvaris in the fourth quarter valued at $110,000.

Pharvaris Trading Down 0.6%

NASDAQ:PHVS opened at $37.00 on Thursday. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $38.13. The stock has a 50-day moving average price of $34.47 and a two-hundred day moving average price of $30.64. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -12.13 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Sell-side analysts forecast that Pharvaris N.V. will post -3.15 earnings per share for the current year.

Insiders Place Their Bets

In other Pharvaris news, insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the sale, the insider directly owned 93,969 shares in the company, valued at approximately $3,334,959.81. This trade represents a 24.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Berndt Modig sold 2,292 shares of Pharvaris stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the transaction, the chief executive officer directly owned 130,625 shares in the company, valued at approximately $4,541,831.25. The trade was a 1.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 121,325 shares of company stock valued at $4,270,425 in the last quarter. 11.84% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the company. UBS Group set a $74.00 price objective on Pharvaris in a research report on Wednesday, May 13th. Royal Bank Of Canada boosted their price target on shares of Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research note on Thursday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.08.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.